Abstract 963P
Background
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Early detection of HCC is critical for timely treatment and a better prognosis. In this prospective study (ASCEND-Hep, NCT04835675), we aimed to explore multi-omics including cell-free DNA (cfDNA) methylation, mutation, and α-fetoprotein (AFP) in early detection of HCC.
Methods
This multicenter study prospectively collected blood samples from patients with HCC and benign liver diseases. Age-matched non-cancer controls were obtained from a previous study. Methylation and mutation were detected through a methylation panel of 161,984 CpG sites and a cancer-associated 168-gene panel, respectively. Models were developed in a training set (cancer: 172; non-cancer: 206) and tested in a validation set (cancer: 117; non-cancer: 140). Then the locked models were validated in an independent validation set (cancer: 158; non-cancer: 637).
Results
In the training set, cfDNA methylation model had a higher area under curve than AFP and mutation alone (P<0.05). In the validation set, the methylation model yielded an overall sensitivity of 92.3% (95% CI, 85.9%–96.4%) at a specificity of 95.0% (90.0%–98.0%). Meanwhile, AFP >400 ng/mL had a sensitivity of 27.3% (18.8%–37.2%) with a specificity of 100.0% (96.5%–100.0%). Combining cfDNA methylation and AFP showed a better performance with a sensitivity of 94.0% (88.1%–97.6%) and a specificity of 95.0% (90.0%–98.0%), while the addition of mutation did not further improve the performance. Consistent results were observed in the independent validation set that the combined model achieved a sensitivity of 90.5% (84.8%–94.6%) at a specificity of 97.3% (95.8%–98.4%). The sensitivity of the combined model in Barcelona Clinic Liver Cancer Classification 0–A was 87.1% (78.0%–93.4%).
Conclusions
cfDNA methylation yielded superior performance than AFP and mutation alone. Our study highlights a potential clinical utility of combining cfDNA methylation and AFP for HCC early detection.
Clinical trial identification
NCT04835675.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Burning Rock Bioengineering Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18